Drug-induced lupus erythematosus (DILE) is an autoimmune disorder like systemic lupus erythematosus (SLE) and both can present with arthralgia, myalgia, fatigue, and serositis. DILE occurs in the setting of chronic drug exposure, usually months after starting the drug, and given the delayed temporal association, DILE can be easily missed. DILE resolves within weeks of drug discontinuation. Drugs also may induce subacute cutaneous lupus erythematous (DISCLE) which, has predominantly skin findings. The most common drugs which cause DILE are hydralazine, procainamide, isoniazid, minocycline, diltiazem and TNF inhibitors. The classic drug associated with DISCLE is hydrochlorothiazide. Drugs that are of high risk for inducing DISCLE include terbinafine (odds ratio of 53), TNF antagonist (OR 8), anti-epileptics (OR 3.4), and proton pump inhibitor(PPI) (OR 2.9). Other drugs classically associated with DISCLE include NSAIDS, calcium channesl blockers (CaCB), and ACE inhibitors. Drugs that can cause both DiSCLE and DLE include terbinafine, TNF antagonists, and anti-epileptics. 
DILE differs clinically from SLE . DILE tends to have less end-organ damage than SLE, and renal and central nervous system (CNS) involvement is uncommon. A few drugs that cause drug-induced lupus are notable exceptions: hydralazine, penicillamine, and TNF-alpha inhibitors commonly involve the kidneys while minocycline has been associated with increased hepatic involvement. Skin findings are also less common in DILE compared to SLE, and DILE tends to be less photosensitive than SLE with the exception of drugs known to cause photosensitivity, such as thiazide diuretic induced subacute lupus erythematous. Moreover, DILE usually presents with a higher incidence of purpura and erythema nodosum and has a decreased incidence of Raynaud compared to SLE.
DILE usually has a slow onset, starting at least three weeks after initiation of a drug (usually within several months to two years), while drug-induced flares of SLE occur much quicker following exposure. If a patient without a history of SLE is clinically suspected of DILE and a quick temporal correlation is noted from the onset of the drug, then suspect previous prior exposure to the drug as it is possible that patient was exposed to the drug before, even if he or she does not remember it.
Furthermore, DILE can be differentiated from SLE by epidemiological factors. SLE tends to occur in young African-American females, while DILE is most commonly a disease of elderly whites with no sexual predilection.
Drugs can induce a subacute cutaneous lupus erythematosus reaction (DISCLE) with some believing up to 30% of SCLE are secondary to drugs. There is a genetic predisposition to DISCLE, with increased frequency of HLA-B8 and HLA DR3. DISCLE compared to SCLE tends to be more widespread with a more severe presentation including a higher prevalence of malar lesions, vasculitis, bulla, and erythema multiforme-like lesions. Visceral manifestations are not seen in DISCLE like in SCLE. DISCLE always affects the skin and tends to be photosensitive and located on the upper body including the lateral face, neck, trunk (especially sun exposed areas like the V of the chest). Morphologically, DISCLE presents as a papulosquamous psoriasiform to a lichenoid eruption, but it also can have a scaly annular morphology with central clearing. SCLE is associated with anti-Ro/SS-A positivity greater than 3/4 of the time, speckled ANA, and 30% postiivity with anti-La/SS-B.
For drug-induced lupus, two drugs have approximately 20% risk with chronic use: hydralazine and procainamide. Five broad classes of medications that can be associated with DILE include: (1) anti-TNF-alpha agents ( etanercept and infliximab) (2) antimicrobials including terbinafine (also associated with SCLE), minocycline (DILE with a higher incidence of hepatitis), and tuberculosis medications including isoniazid, pyrazinamide, and rifabutin, (3) anticonvulsants such as phenytoin, valproate, carbamazepine, (4) antiarrhythmic drugs such as procainamide, quinidine, and propafenone, and (5) antihypertensives such as hydroxyzine, minoxidil, and timolol (usually beta-blockers are not associated with DILE).
The most common cause of DISCLE is hydrochlorothiazide given its frequent use in the elderly population. Terbinafine may have the highest risk associated with developing DISCLE, another antifungal, griseofulvin is also associated with the development of DISCLE. Other drugs associated with DISCLE include PPI, NSAIDS (piroxicam), CaCB, ACEI, and docetaxel. Drugs that can cause both DISCLE and DLE include terbinafine, TNF antagonists, and anti-epileptics.
Drug-induced lupus tends to occur in patients older than fifty years, with increased incidence among whites and no sexual predilection. Comparatively, SLE tends to occur in younger patients with a predilection for females. Slow acetylation is at increased risk of DILE, and the frequency of HLA DR-4 is increased in a subset studied with drug-induced lupus erythematosus.
The pathophysiology of DILE is unclear and different mechanisms are responsible for the induction of autoimmunity by different lupus-inducing drugs. Slow acetylator status, HLA-DR4, HLA-DR2, HLA-DR3 and complement factor C4 null allele are risk factors for DILETheories have included reactive metabolites of medications leading to increased lupus-like antibody formation directly or indirectly via decrease T cell methylation with increased expression of LFA-1. Slow acetylators with genetic deficiency of N-acetyltransferase are known to be at higher risk of drug-induced lupus erythematosus.
A high clinical suspicion is required for drug-induced lupus for a patient presenting with non-specific complaints of fever, fatigue, arthralgia, myalgia, and weight loss. Drug-induced lupus can be hard to diagnose as the symptoms often start months to years after initiation of the drug. It is difficult to differentiate DILE and idiopathic SLE based on the signs and symptoms. Arthralgia is common and often is the first symptom and presents in up to 90% of the patients. Myalgia, fever, pleurisy, and pericarditis are also common. Central nervous system and renal involvement are very rare. Photosensitivity, purpura and erythema nodosum are more frequent in DILE, and malar rash, alopecia, discoid lesions, and mucosal ulcers are less common in DILE than in SLE. However, any dermatological manifestation of SLE should prompt a careful review of a patient’s medication list.
A thorough physical exam should be performed. DILE is less likely to have visceral involvement, so exam findings such as hepatosplenomegaly, serositis manifestations of pleurisy and pericarditis, and neurologic findings are less common.
Laboratory testing can be performed including complete blood (cell) count, cytidine 5´ phosphate, urinalysis, complement levels, Antibody assays including ANA, dsDNA, anti-Ro, anti-histone, anti-Smith, and other autoimmune disorders of suspicion. In DISCLE, suspect complement deficiencies, especially in the early intrinsic pathway involving C1q/r/s, C2, and C4. DILE, unlike DISCLE or SLE, is not associated with changes in the complement level. DILE is less likely to show anemia or thrombocytopenia on complete blood count, a decrease in C3 and C4 levels, or abnormalities of the liver and kidney function tests and urine analysis. Antibody testing also will show differences between DILE and SLE. Both DILE and SLE are ANA positive, and although anti-histones are classically associated with DILE, they can also occur in up to 50% of SLE patients. Anti-Smith, ds-DNA are specific for SLE whereas positive ss-DNA is more commonly found in DILE.
Skin biopsy for drug-induced lupus is indistinguishable from SLE.
Treatment is discontinuation of medication. Symptoms should resolve within weeks of stopping the medications. If symptoms are severe, corticosteroids and NSAIDS can be given. Appropriate monitoring of viscera is indicated in the rare incidence with viscera involvement.
Many drugs can induce lupus and often these patients will present to the nurse practitioner, primary care provider, internist and the rheumatologist. However, it is important to get a proper drug history because the diagnosis may not be straight forward. In most cases, once the offending drug is discontinued, the symptoms gradually subside. However, if there is any organ dysfunction, then the patient needs to be monitored until the laboratory parameters are normal. The pharmacist should always keep a track of patient medications because it may be the first clue that a drug is involved in the patient's pathology. an interprofessional team approach to the evaluation and treatment of drug-induced lupus will provide the best outcome. [Level V]
|||Tierney E,Kirthi S,Ramsay B,Ahmad K, Ustekinumab-induced subacute cutaneous lupus. JAAD case reports. 2019 Mar; [PubMed PMID: 30891478]|
|||Arnaud L,Mertz P,Gavand PE,Martin T,Chasset F,Tebacher-Alt M,Lambert A,Muller C,Sibilia J,Lebrun-Vignes B,Salem JE, Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Annals of the rheumatic diseases. 2019 Apr; [PubMed PMID: 30793701]|
|||Guicciardi F,Atzori L,Marzano AV,Tavecchio S,Girolomoni G,Colato C,Villani AP,Kanitakis J,Mitteldorf C,Satta R,Cribier B,Gusdorf L,Rossi MT,Calzavara-Pinton P,Bielsa I,Fernandez-Figueras MT,Kempf W,Filosa G,Pilloni L,Rongioletti F, Are there distinct clinical and pathological features distinguishing Idiopathic from Drug-Induced Subacute Cutaneous Lupus Erythematosus? A European retrospective multicenter study. Journal of the American Academy of Dermatology. 2019 Feb 11; [PubMed PMID: 30763648]|
|||Sosenko T,Pasula S,Brahmamdam R,Girnita D, When Chest Pain Reveals More: A Case of Hydrochlorothiazide-Induced Systemic Lupus Erythematosus. The American journal of case reports. 2019 Jan 7; [PubMed PMID: 30613100]|
|||Batra J,Kaur S,Kaushal S,Singh A, Lamotrigine-induced Systemic Lupus Erythematosus: A Diagnostic Dilemma. Indian dermatology online journal. 2018 Nov-Dec; [PubMed PMID: 30505789]|
|||Skovmøller KB,Bygum A, [When drugs induce cutaneous lupus erythematosus]. Ugeskrift for laeger. 2018 Oct 8; [PubMed PMID: 30327081]|
|||Vaglio A,Grayson PC,Fenaroli P,Gianfreda D,Boccaletti V,Ghiggeri GM,Moroni G, Drug-induced lupus: Traditional and new concepts. Autoimmunity reviews. 2018 Sep; [PubMed PMID: 30005854]|
|||He Y,Sawalha AH, Drug-induced lupus erythematosus: an update on drugs and mechanisms. Current opinion in rheumatology. 2018 Sep; [PubMed PMID: 29870500]|
|||Bojinca VC,Bojinca M,Gheorghe M,Birceanu A,Iosif CI,Balanescu SM,Balanescu AR, Stevens-Johnsons syndrome or drug-induced lupus - a clinical dilemma: A case report and review of the literature. Biomedical reports. 2018 Jul; [PubMed PMID: 29930803]|
|||Richardson B, The interaction between environmental triggers and epigenetics in autoimmunity. Clinical immunology (Orlando, Fla.). 2018 Jul; [PubMed PMID: 29649575]|
|||Dalle Vedove C,Simon JC,Girolomoni G, Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2012 Dec; [PubMed PMID: 22937775]|
|||Kelly AS,De la Harpe Golden P,D'Arcy C,Lally A, Drug-induced lupus erythematosus secondary to pirfenidone. The British journal of dermatology. 2018 Jun; [PubMed PMID: 29266198]|
|||Sarkar R,Paul R,Pandey R,Roy D,Sau TJ,Mani A,Ruia AV,Mondal J, Drug-induced Lupus Presenting with Myocarditis. The Journal of the Association of Physicians of India. 2017 Jun; [PubMed PMID: 28782328]|
|||Zeitjian V,Mehdizadeh A, ANA-Negative Hydralazine-Induced Pericardial Effusion. Case reports in medicine. 2017; [PubMed PMID: 29391867]|
|||Laurinaviciene R,Sandholdt LH,Bygum A, Drug-induced cutaneous lupus erythematosus: 88 new cases. European journal of dermatology : EJD. 2017 Feb 1; [PubMed PMID: 27799135]|
|||REINHARDT DJ,WALDRON JM, Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. Journal of the American Medical Association. 1954 Aug 21; [PubMed PMID: 13183772]|
|||Chang C,Gershwin ME, Drug-induced lupus erythematosus: incidence, management and prevention. Drug safety. 2011 May 1; [PubMed PMID: 21513360]|